CytoSorbents Corporation (CTSO)

[Good Sport]

H.C. Wainwright Reaffirms Their Buy Rating on Cytosorbents (CTSO)
September 28 2022 - 06:25AM
TipRanks

H.C. Wainwright analyst Sean Lee CFA maintained a Buy rating on Cytosorbents ( – ) today and set a price target of $9.00. The company’s shares closed yesterday at $1.39.

Lee CFA covers the Healthcare sector, focusing on stocks such as Plus Therapeutics, Verastem, and Cytosorbents. According to , Lee CFA has an average return of -22.9% and a 16.49% success rate on recommended stocks.

Currently, the analyst consensus on Cytosorbents is a Moderate Buy with an average price target of $16.00.

CTSO market cap is currently $60.57M and has a P/E ratio of -1.70.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which are most likely to make moves following their insider activities.

CytoSorbents Corp. engages in the research and development of blood purification technology for the reduction of deadly uncontrolled inflammation in hospitalized patients. Its product include CytoSorb, ContrastSorb, HemoDefend, VetResQ, and DrugSorb. The company was founded by Joseph Rubin on April 25, 2002 and is headquartered in Monmouth Junction, NJ.

tipranks
TipRanks is a comprehensive investing tool that allows private investors and day traders to see the measured performance of anyone who provides financial advice.

https://www.tipranks.com/news/blurbs/h-c-wainwright-reaffirms-their-buy-rating-on-cytosorbents-ctso?utm_source=advfn.com&utm_medium=referral